Trial Profile
An Open-Label,Single-Arm,Phase I Clinical Trial to Evaluate the Pharmacokinetics,Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer,Fallopian Tube Cancer and Primary Peritoneal Cancer (Collectively Termed as Ovarian Cancer)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2020
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacokinetics
- Sponsors ZAI Lab
- 03 Apr 2019 A population PK model was derived using pooled datea from 3 trials (NCT03551171, ENGOT-OV16/NOVA sub-study and the dose escalation and expansion study (PN001) ) ;results presented at the 110th Annual Meeting of the American Association for Cancer Research
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 New trial record